Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

NCT02691325 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK2269557 ELLIPTA DPI
DRUG: Placebo ELLIPTA DPI
DRUG: Activated charcoal

Sponsor

GlaxoSmithKline